Does the media refer more to MRKR or PEPG?

In the previous week, PepGen had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 2 mentions for PepGen and 1 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 0.94 beat PepGen's score of 0.51 indicating that Marker Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Marker Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PepGen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BMEA or MRKR?

In the previous week, Biomea Fusion had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 2 mentions for Biomea Fusion and 1 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 0.94 beat Biomea Fusion's score of 0.62 indicating that Marker Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomea Fusion 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Marker Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MRKR or LFVN?

In the previous week, Lifevantage had 2 more articles in the media than Marker Therapeutics. MarketBeat recorded 3 mentions for Lifevantage and 1 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 0.94 beat Lifevantage's score of 0.65 indicating that Marker Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Marker Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lifevantage 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VRCA or MRKR?

In the previous week, Verrica Pharmaceuticals and Verrica Pharmaceuticals both had 1 articles in the media. Marker Therapeutics' average media sentiment score of 0.94 beat Verrica Pharmaceuticals' score of 0.63 indicating that Marker Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Marker Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MRKR or PMN?

In the previous week, Marker Therapeutics and Marker Therapeutics both had 1 articles in the media. Marker Therapeutics' average media sentiment score of 0.94 beat Promis Neurosciences' score of 0.63 indicating that Marker Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Marker Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Promis Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Marker Therapeutics (MRKR) Competitors

$1.47 +0.02 (+1.38%)

Closing price 04:00 PM Eastern

Extended Trading

$1.47 0.00 (0.00%)

As of 04:04 PM Eastern

Compare

MRKR vs. PEPG, BMEA, LFVN, VRCA, and PMN

Should you buy Marker Therapeutics stock or one of its competitors? MarketBeat compares Marker Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Marker Therapeutics include PepGen (PEPG), Biomea Fusion (BMEA), Lifevantage (LFVN), Verrica Pharmaceuticals (VRCA), and Promis Neurosciences (PMN). These companies are all part of the "pharmaceutical products" industry.

How does Marker Therapeutics compare to PepGen?

Marker Therapeutics (NASDAQ:MRKR) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Marker Therapeutics has higher revenue and earnings than PepGen. Marker Therapeutics is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	6.90	-$12.16M	-$0.61	N/A
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A

In the previous week, PepGen had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 2 mentions for PepGen and 1 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 0.94 beat PepGen's score of 0.51 indicating that Marker Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Marker Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PepGen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

PepGen has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. PepGen's return on equity of -59.89% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-73.29%	-59.70%
PepGen	N/A	-59.89%	-49.62%

Marker Therapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 580.27%. PepGen has a consensus price target of $11.60, suggesting a potential upside of 683.78%. Given PepGen's stronger consensus rating and higher possible upside, analysts plainly believe PepGen is more favorable than Marker Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

22.4% of Marker Therapeutics shares are held by institutional investors. Comparatively, 58.0% of PepGen shares are held by institutional investors. 5.7% of Marker Therapeutics shares are held by company insiders. Comparatively, 1.3% of PepGen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Marker Therapeutics has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market. Comparatively, PepGen has a beta of 1.93, indicating that its share price is 93% more volatile than the broader market.

Summary

PepGen beats Marker Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Marker Therapeutics compare to Biomea Fusion?

Biomea Fusion (NASDAQ:BMEA) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

96.7% of Biomea Fusion shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 10.6% of Biomea Fusion shares are owned by company insiders. Comparatively, 5.7% of Marker Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Marker Therapeutics has higher revenue and earnings than Biomea Fusion. Marker Therapeutics is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A
Marker Therapeutics	$3.55M	6.90	-$12.16M	-$0.61	N/A

Biomea Fusion currently has a consensus target price of $8.50, suggesting a potential upside of 522.71%. Marker Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 580.27%. Given Marker Therapeutics' higher possible upside, analysts clearly believe Marker Therapeutics is more favorable than Biomea Fusion.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Biomea Fusion had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 2 mentions for Biomea Fusion and 1 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 0.94 beat Biomea Fusion's score of 0.62 indicating that Marker Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biomea Fusion	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Marker Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biomea Fusion has a beta of -0.31, suggesting that its share price is 131% less volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market.

Biomea Fusion has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
Marker Therapeutics	-343.03%	-73.29%	-59.70%

Summary

Marker Therapeutics beats Biomea Fusion on 8 of the 15 factors compared between the two stocks.

How does Marker Therapeutics compare to Lifevantage?

Marker Therapeutics (NASDAQ:MRKR) and Lifevantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

22.4% of Marker Therapeutics shares are held by institutional investors. Comparatively, 35.3% of Lifevantage shares are held by institutional investors. 5.7% of Marker Therapeutics shares are held by company insiders. Comparatively, 22.0% of Lifevantage shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Marker Therapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 580.27%. Lifevantage has a consensus price target of $5.00, suggesting a potential downside of 46.29%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Marker Therapeutics is more favorable than Lifevantage.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Lifevantage	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Marker Therapeutics has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market. Comparatively, Lifevantage has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

In the previous week, Lifevantage had 2 more articles in the media than Marker Therapeutics. MarketBeat recorded 3 mentions for Lifevantage and 1 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 0.94 beat Lifevantage's score of 0.65 indicating that Marker Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Marker Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lifevantage	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lifevantage has higher revenue and earnings than Marker Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	6.90	-$12.16M	-$0.61	N/A
Lifevantage	$195.32M	0.60	$9.81M	$0.45	20.69

Lifevantage has a net margin of 2.94% compared to Marker Therapeutics' net margin of -343.03%. Lifevantage's return on equity of 23.89% beat Marker Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-73.29%	-59.70%
Lifevantage	2.94%	23.89%	12.47%

Summary

Lifevantage beats Marker Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Marker Therapeutics compare to Verrica Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Verrica Pharmaceuticals currently has a consensus target price of $14.50, suggesting a potential upside of 135.77%. Marker Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 580.27%. Given Marker Therapeutics' higher probable upside, analysts plainly believe Marker Therapeutics is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Verrica Pharmaceuticals has a net margin of -47.97% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%
Marker Therapeutics	-343.03%	-73.29%	-59.70%

Marker Therapeutics has lower revenue, but higher earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Marker Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.97	-$17.89M	-$1.03	N/A
Marker Therapeutics	$3.55M	6.90	-$12.16M	-$0.61	N/A

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 54.0% of Verrica Pharmaceuticals shares are held by company insiders. Comparatively, 5.7% of Marker Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Verrica Pharmaceuticals has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market.

In the previous week, Verrica Pharmaceuticals and Verrica Pharmaceuticals both had 1 articles in the media. Marker Therapeutics' average media sentiment score of 0.94 beat Verrica Pharmaceuticals' score of 0.63 indicating that Marker Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Marker Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Marker Therapeutics beats Verrica Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Marker Therapeutics compare to Promis Neurosciences?

Marker Therapeutics (NASDAQ:MRKR) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Marker Therapeutics has a beta of 1.44, meaning that its share price is 44% more volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.19, meaning that its share price is 119% less volatile than the broader market.

22.4% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are owned by institutional investors. 5.7% of Marker Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Promis Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Marker Therapeutics has higher revenue and earnings than Promis Neurosciences. Marker Therapeutics is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	6.90	-$12.16M	-$0.61	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A

In the previous week, Marker Therapeutics and Marker Therapeutics both had 1 articles in the media. Marker Therapeutics' average media sentiment score of 0.94 beat Promis Neurosciences' score of 0.63 indicating that Marker Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Marker Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Promis Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Marker Therapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 580.27%. Promis Neurosciences has a consensus price target of $26.50, suggesting a potential upside of 172.35%. Given Marker Therapeutics' higher possible upside, analysts clearly believe Marker Therapeutics is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Promis Neurosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Promis Neurosciences has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-73.29%	-59.70%
Promis Neurosciences	N/A	-237.99%	-151.04%

Summary

Marker Therapeutics beats Promis Neurosciences on 9 of the 14 factors compared between the two stocks.

Get Marker Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRKR vs. The Competition

Export

Metric	Marker Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$24.51M	$2.97B	$6.44B	$12.47B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	-2.41	18.12	23.87	24.40
Price / Sales	6.90	303.58	521.86	117.01
Price / Cash	N/A	55.72	41.27	57.13
Price / Book	1.46	3.94	9.99	6.73
Net Income	-$12.16M	$75.85M	$3.56B	$337.03M
7 Day Performance	-2.65%	-1.12%	-0.87%	0.11%
1 Month Performance	N/A	N/A	N/A	-1.70%
1 Year Performance	-2.65%	23.05%	28.77%	34.24%

Marker Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRKR Marker Therapeutics	2.2395 of 5 stars	$1.47 +1.4%	$10.00 +580.3%	-4.6%	$24.51M	$3.55M	N/A	60	Short Interest Increase
PEPG PepGen	2.8181 of 5 stars	$1.43 -5.0%	$11.60 +714.0%	-7.2%	$103.75M	N/A	N/A	30	Analyst Downgrade
BMEA Biomea Fusion	2.0348 of 5 stars	$1.43 +3.3%	$8.29 +481.5%	-47.8%	$99.77M	N/A	N/A	50
LFVN Lifevantage	2.9778 of 5 stars	$9.48 +20.4%	$5.00 -47.2%	-35.3%	$99.29M	$228.53M	23.07	260	Ex-Dividend High Trading Volume
VRCA Verrica Pharmaceuticals	2.8282 of 5 stars	$6.03 +4.6%	$14.50 +140.7%	+10.5%	$98.95M	$37.16M	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRKR) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Marker Therapeutics (MRKR) Competitors

MRKR vs. PEPG, BMEA, LFVN, VRCA, and PMN

How does Marker Therapeutics compare to PepGen?

Summary

How does Marker Therapeutics compare to Biomea Fusion?

Summary

How does Marker Therapeutics compare to Lifevantage?

Summary

How does Marker Therapeutics compare to Verrica Pharmaceuticals?

Summary

How does Marker Therapeutics compare to Promis Neurosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRKR vs. The Competition

Marker Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Marker Therapeutics (MRKR) Competitors

MRKR vs. PEPG, BMEA, LFVN, VRCA, and PMN

How does Marker Therapeutics compare to PepGen?

Which has better earnings & valuation, MRKR or PEPG?

Does the media refer more to MRKR or PEPG?

Is MRKR or PEPG more profitable?

Do analysts rate MRKR or PEPG?

Do insiders & institutionals believe in MRKR or PEPG?

Which has more volatility and risk, MRKR or PEPG?

Summary

How does Marker Therapeutics compare to Biomea Fusion?

Do insiders and institutionals hold more shares of BMEA or MRKR?

Which has stronger valuation & earnings, BMEA or MRKR?

Do analysts rate BMEA or MRKR?

Does the media favor BMEA or MRKR?

Which has more volatility & risk, BMEA or MRKR?

Is BMEA or MRKR more profitable?

Summary

How does Marker Therapeutics compare to Lifevantage?

Do institutionals & insiders hold more shares of MRKR or LFVN?

Do analysts prefer MRKR or LFVN?

Which has more risk & volatility, MRKR or LFVN?

Does the media refer more to MRKR or LFVN?

Which has higher earnings & valuation, MRKR or LFVN?

Is MRKR or LFVN more profitable?

Summary

How does Marker Therapeutics compare to Verrica Pharmaceuticals?

Do analysts prefer VRCA or MRKR?

Is VRCA or MRKR more profitable?

Which has better valuation & earnings, VRCA or MRKR?

Do institutionals and insiders hold more shares of VRCA or MRKR?

Which has more risk and volatility, VRCA or MRKR?

Does the media prefer VRCA or MRKR?

Summary

How does Marker Therapeutics compare to Promis Neurosciences?

Which has more volatility & risk, MRKR or PMN?

Do institutionals & insiders hold more shares of MRKR or PMN?

Which has preferable earnings & valuation, MRKR or PMN?

Does the media favor MRKR or PMN?

Do analysts recommend MRKR or PMN?

Is MRKR or PMN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRKR vs. The Competition

Marker Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools